By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,701.53 today based on a price of $771.99 for LLY at the time of writing.

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Health news highlights the booming demand for obesity drugs in India with companies like Eli Lilly and Novo Nordisk vying for ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...